


# PRODUCT INFORMATION



## Stearda

Item No. 38973

**CAS Registry No.:** 105955-10-0  
**Formal Name:** N-[2-(3,4-dihydroxyphenyl)ethyl]-  
octadecanamide  
**Synonyms:** N-octadecanoyl Dopamine,  
N-Stearoyl Dopamine  
**MF:** C<sub>26</sub>H<sub>45</sub>NO<sub>3</sub>  
**FW:** 419.6  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Stearda is supplied as a solid. A stock solution may be made by dissolving the stearda in the solvent of choice, which should be purged with an inert gas. Stearda is soluble in DMSO. Stearda is slightly soluble in chloroform and methanol.

### Description

Stearda is an endogenous fatty acid amide composed of the catecholamine dopamine (Item Nos. 36532 | 21992) conjugated to the long-chain saturated fatty acid stearic acid (Item No. 10011298).<sup>1</sup> It is an inhibitor of 5-lipoxygenase (5-LO; IC<sub>50</sub> = 16 nM). Stearda is cytotoxic to K562 chronic myeloid leukemia cells, HOS osteosarcoma fibroblasts, and IMR-32 neuroblastoma cells but not MCF-7 breast cancer cells (IC<sub>50</sub>s = 36.8, 15, 1.5, and >100 μM, respectively).<sup>2</sup> It potentiates calcium influx induced by the arachidonoyl amino acid and cannabinoid 1 (CB<sub>1</sub>) receptor agonist N-arachidonoyl dopamine (NADA; Item No. 90057) in HEK293 cells expressing human transient receptor potential vanilloid 6 (TRPV6) when used at concentrations of 1 or 10 μM.<sup>3</sup> *In vivo*, stearda (0.1 mg/ml per paw), in combination with NADA, decreases latency to paw withdrawal in the hot plate test in rats.

### References

1. Iwakami, S., Shibuya, M., Tseng, C.F., *et al.* Inhibition of arachidonate 5-lipoxygenase by phenolic compounds. *Chem. Pharm. Bull. (Tokyo)* **34(9)**, 3960-3963 (1986).
2. Akimov, M., Gretskeya, N.M., Zinchenko, G.N., *et al.* Cytotoxicity of endogenous lipids N-acyl dopamines and their possible metabolic derivatives for human cancer cell lines of different histological origin. *Anticancer Res.* **35(5)**, 2657-2662 (2015).
3. De Petrocellis, L., Chu, C.J., Moriello, A.S., *et al.* Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. *Br. J. Pharmacol.* **143(2)**, 251-256 (2004).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/15/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM